Long-Term Outcomes Following Left Atrial Appendage Occlusion in Medicare Beneficiaries: Outcomes From the National

Angela Y Higgins1, Sarah Zimmerman2,3, Yongfei Wang2,3

  • 1Department of Cardiovascular Medicine Maine Medical Center Portland ME USA.

Insights

Left atrial appendage occlusion (LAAO) effectively prevents stroke in atrial fibrillation patients. Long-term data shows low stroke rates but high mortality in elderly individuals, emphasizing personalized care decisions.

Area of Science:

  • Cardiology
  • Medical Devices
  • Public Health

Background:

  • Percutaneous left atrial appendage occlusion (LAAO) offers an alternative to anticoagulation for stroke prevention in atrial fibrillation.
  • Limited long-term outcomes data exists for real-world LAAO patient populations.

Purpose of the Study:

  • To evaluate long-term stroke rates and all-cause mortality in elderly patients undergoing LAAO with a WATCHMAN device.
  • To assess the durability of LAAO for stroke prevention in a real-world setting.

Main Methods:

  • Retrospective cohort study using the National Cardiovascular Data Registry LAAO registry (2016-2019).
  • Linked LAAO data with Medicare claims for patients aged 65+ receiving WATCHMAN device.
  • Primary outcomes: any stroke and all-cause mortality.

Main Results:

  • Included 34,975 patients with a high mean CHA 2 DS 2 -VASc score (4.7±1.4).
  • 1-year and 5-year stroke estimates were 1.70% and 5.70%, respectively.
  • 5-year mortality estimate was 44.34% in this elderly cohort.

Conclusions:

  • Long-term stroke rates after LAAO are low and consistent in Medicare patients, even with high thromboembolic risk.
  • High mortality rates highlight the need for shared decision-making, incorporating patient values and preferences.
Abstract

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
28
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30